Phase 3 respiratory company with novel anti-fungal therapy for invasive aspergillosis patients including acute and chronic infections.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2013
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
Opelconazole
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
one
Speaker
